Rivaroxaban

also known as Xarelto · BAY59-7939 · Rivaroxaban (Xarelto) · JNJ39039039 · Rivaroxaban accord · Rivaroxaban viatris (previously rivaroxaban mylan) · Rivaroxabana · Rovaltro · +1 more

Other / unclassified targets F10 via inhibition

Developed for: venous thromboembolism · atrial fibrillation · thrombotic disease · coronary artery disorder · peripheral arterial disease · acute coronary syndrome · ischemic stroke · stroke disorder
+75 more
· pulmonary embolism · COVID-19 · ST-elevation myocardial infarction · cancer · antiphospholipid syndrome · cerebral sinovenous thrombosis · cirrhosis of liver · heart failure · intracerebral hemorrhage · myocardial infarction · neoplasm · portal vein thrombosis · cardiac valvular defect · rheumatic heart disease · thrombophlebitis · transient ischemic attack · aortic valve disorder · aortic valve stenosis · arterial occlusion · coronary aneurysm · end stage renal failure · impaired renal function disease · intermediate coronary syndrome · intracranial arteriosclerosis · Kawasaki disease · May-Thurner syndrome · migraine disorder · mitral valve stenosis · plasma cell myeloma · sickle cell disease · vascular ectasia · acquired polycythemia vera · atherosclerosis · atrial flutter · Behcet disease · blood coagulation disease · brain ischemia · cardiac rhythm disease · cardiovascular disorder · carotid stenosis · cerebral atherosclerosis · cerebral infarction · chronic kidney disease · chronic obstructive pulmonary disease · diabetes mellitus, noninsulin-dependent, 2 · esophageal varices with bleeding · essential thrombocythemia · heart valve disorder · heparin-induced thrombocytopenia · hyperheparinemia · hypertrophic cardiomyopathy · idiopathic membranous glomerulonephritis · intermittent vascular claudication · intracranial arterial disease · intracranial embolism · isolated mesenteric vein thrombosis · isolated splenic vein thrombosis · limb ischemia · malignant glioma · malignant urinary system neoplasm · mitral valve insufficiency · postoperative ventricular dysfunction · primary myelofibrosis · severe acute respiratory syndrome · sickle cell-beta zero-thalassemia · systemic lupus erythematosus · bleeding disorder, vascular-type · calcinosis · coronary atherosclerosis · diabetes mellitus · infective endocarditis · post-thrombotic syndrome · staphylococcal toxemia · staphylococcus aureus infection · traumatic brain injury
Investigated by: Bayer · Janssen Research & Development, LLC · Janssen Scientific Affairs, LLC · Population Health Research Institute · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Assistance Publique - Hôpitaux de Paris
+313 more
· Insel Gruppe AG, University Hospital Bern · Ottawa Hospital Research Institute · Second Affiliated Hospital, School of Medicine, Zhejiang University · National Heart, Lung, and Blood Institute (NHLBI) · Seoul National University Hospital · Shanghai Zhongshan Hospital · Hamilton Health Sciences Corporation · Radboud University Medical Center · Science Valley Research Institute · University Hospital of Saint-Etienne · Asan Medical Center · Canadian Institutes of Health Research (CIHR) · China National Center for Cardiovascular Diseases · Imperial College London · Ottawa Heart Institute Research Corporation · RenJi Hospital · Rigshospitalet, Denmark · The Ottawa Hospital · University Hospital, Angers · University Hospital, Brest · University of Florida · Xijing Hospital · Yonsei University · Aalborg University Hospital · Aarhus University Hospital · Anhui Provincial Hospital · Centre Hospitalier Universitaire Vaudois · Charite University, Berlin, Germany · Children's Hospital of Fudan University · Chinese Academy of Medical Sciences, Fuwai Hospital · Chonnam National University Hospital · GWT-TUD GmbH · Gødstrup Hospital · Heart and Stroke Foundation of Canada · Hospital Universitari Vall d'Hebron Research Institute · Huadong Hospital · Huashan Hospital · Instituto Nacional de Cardiologia Ignacio Chavez · Korea University Anam Hospital · Massachusetts General Hospital · McMaster University · Medical University of Graz · Medical University of South Carolina · Medtronic · Ministry of Health, France · Northwestern University · Odense University Hospital · Onze Lieve Vrouw Hospital · Oslo University Hospital · Queen Elizabeth II Health Sciences Centre · Rajaie Cardiovascular Medical and Research Center · Regeneron Pharmaceuticals · Seoul National University Bundang Hospital · Shanghai 5th People's Hospital · Sir Run Run Shaw Hospital · The First Affiliated Hospital with Nanjing Medical University · University College, London · University of Alberta · University of Cape Town · University of Padova · University of Sao Paulo General Hospital · Vanderbilt University Medical Center · Yantai Yuhuangding Hospital · AHEPA University Hospital · AIO-Studien-gGmbH · AZ Sint-Jan AV · Aalborg University · Abbott · Abidi Pharmaceuticals · Academisch Ziekenhuis Groningen · Action Research Group · Addpharma Inc. · Affiliated Hospital of Jiaxing University · Ahmed AbdelMoneim Hassan Ali · all 319 on the full record

Regulatory milestones approvals, filings & regulatory actions · 18 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed limb ischemia 1 milestone
Filed	US (FDA)	Xarelto	limb ischemia	2017-12-11	“has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the rivaroxaban (Xarelto®) vascular dose” bayer.com ↗ “Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban)” jnj.com ↗
Filed peripheral arterial occlusive disease 1 1 milestone
Filed	EU (EMA)	Xarelto	peripheral arterial occlusive disease 1	2017-11-06	“Bayer has submitted an application to the European Medicines Agency (EMA) for the marketing authorization of the vascular dose of its Factor Xa inhibitor rivaroxaban” bayer.com ↗
Filed venous thromboembolism 3 milestones
Filed	US (FDA)	Xarelto	venous thromboembolism	2021-06-23	“announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO®(rivaroxaban) in pediatric patients.” jnj.com ↗
Filed	US (FDA)	XARELTO®	venous thromboembolism	2018-12-14	“A supplemental New Drug Application was submitted to the FDA seeking to broaden the use of XARELTO (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood...” jnj.com ↗ “Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients” jnj.com ↗
Filed	US (FDA)	Xarelto	venous thromboembolism	2017-05-01	“a supplemental New Drug Application was submitted to the FDA to update the prescribing information for XARELTO (rivaroxaban)” jnj.com ↗ “UNIVERSE data are included in recent New Drug Application to FDA for two new pediatric indications for rivaroxaban” bayer.com ↗ “included ina recent New Drug Applicationsubmitted to the U.S. Food and Drug Administration” jnj.com ↗
Rejected acute coronary syndrome 2 milestones
Rejected (CRL)	US (FDA)	XARELTO®	acute coronary syndrome	2013-06-28	“FDA Issues Complete Response Letter for XARELTO ® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome” jnj.com ↗
Rejected (CRL)	US (FDA)	XARELTO®	acute coronary syndrome	2013-03-04	“FDA Issues Complete Response Letter for XARELTO ® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome” jnj.com ↗
Approved Indication not stated 4 milestones
Label expansions (8)	US (FDA)	XARELTO	—	2012-11-02 – 2021-08-23	fda.gov ↗
Filed	EU (EMA)	Xarelto	venous thromboembolism in children	2019-11-25	“Bayer has submitted an application to the European Medicines Agency (EMA) to extend the Xarelto marketing authorization” bayer.com ↗
Approved	US (FDA)	XARELTO	—	2011-07-01	fda.gov ↗
Approved	EU (EMA)	Xarelto	—	2008-09-30	europa.eu ↗

Trials 283 · started per year

today

EU approved 2008

US approved 2011

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06961630	Oct 2025 → Mar 2027 expected	myocardial infarction	NYU Langone Health	Recruiting	No outcome recorded
Phase 0	NCT07011095	Sep 2025 → Feb 2027 expected	atrial fibrillation	Population Health Research Institute	Not yet recruiting	No outcome recorded
Phase 0	NCT05308030	Aug 2022 → May 2023	peripheral arterial disease	Assiut University	Unknown	No outcome recorded
Phase 0	NCT04994223	Jul 2021 → Dec 2022	peripheral arterial disease	Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi	Unknown	No outcome recorded
Phase 129 trials · 2 met primary
Phase 1	NCT06913595	Mar 2024 → Oct 2025 overdue	venous thromboembolism	Cairo University	Active not recruiting	No outcome recorded
Phase 1	NCT05723510	Mar → Jul 2023	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT07077954	Jan → Jun 2023	venous thromboembolism	Children Hospital and Institute of Child Health, Lahore	Completed	No outcome recorded
Phase 1	NCT04767776	Jan → Sep 2022	—	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 1	NCT05128591	Nov → Dec 2021	thrombotic disease	Addpharma Inc.	Completed	No outcome recorded
Phase 1	NCT04874428	May 2021 → Jun 2026 overdue	cirrhosis of liver	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 1	NCT05418803	Jan → Feb 2020	—	Yuhan Corporation	Completed	Met primary
Phase 1	NCT04180436	Jan 2020 → Jun 2022	morbid obesity	University Hospital, Brest	Completed	No outcome recorded
Phase 1	NCT03864406	Jun 2019 → Dec 2022	—	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1	NCT03796377	Feb → Apr 2019	—	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT06065592	Feb 2019 → Dec 2024	breast cancer, colorectal cancer, hepatocellular carcinoma, immune system disorder +4	Lebanese University	Unknown	No outcome recorded
Phase 1	NCT04720092	Jul → Aug 2017	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 1	NCT04727021	Jul → Sep 2017	—	Bayer	Completed	No outcome recorded
Phase 1	NCT02832947	Feb → Jun 2016	venous thromboembolism	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT02657512	Jan → Feb 2016	—	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 1	NCT02497716	Nov 2015 → May 2018	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 1	NCT02561923	Aug 2015 → Jun 2016	—	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 1	NCT02438098	Jun → Nov 2015	venous thromboembolism	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT02367027	Feb → Apr 2015	—	Bayer	Completed	No outcome recorded
Phase 1	NCT02289703	Jan → Mar 2015	end stage renal failure	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02058199	Dec 2014 → Dec 2015	—	State University of New York - Upstate Medical University	Terminated	No outcome recorded
Phase 1	NCT01954238	Aug 2013 → Mar 2014	—	Green Cross Corporation	Completed	No outcome recorded
Phase 1	NCT01853800	May → Jul 2013	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01656330	Jul → Aug 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01400646	Oct 2011 → May 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01379300	May → Dec 2011	thrombotic disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01309438	Feb 2011 → Mar 2012	impaired renal function disease	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01145859	Nov 2010 → Jul 2015	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 1	NCT01507051	Nov 2008 → Nov 2009	venous thromboembolism	Bayer	Completed	Met primary

Phase 1/24 trials · 1 met primary
Phase 1/2	NCT03747081	Sep 2018 → Jan 2020	cerebral sinovenous thrombosis	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 1/2	NCT04397289	Feb 2018 → Mar 2021	cirrhosis of liver, hemorrhagic disease, portal hypertension, thrombotic disease	First Affiliated Hospital Xi'an Jiaotong University	Completed	No outcome recorded
Phase 1/2	NCT03282643	Feb 2016 → Jun 2018	neoplasm	Capital Medical University	Completed	Met primary
Phase 1/2	NCT02564718	Nov 2015 → Dec 2017	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 234 trials · 1 met primary · 5 missed
Phase 2	NCT07246005	Dec 2026 → Dec 2027 expected	thrombotic disease	Queen Mary University of London	Not yet recruiting	No outcome recorded
Phase 2	NCT05775965	May 2024 → Mar 2027 expected	—	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT05546320	Oct 2022 → Mar 2025	migraine disorder, patent foramen ovale	Chinese Academy of Medical Sciences, Fuwai Hospital	Completed	No outcome recorded
Phase 2	NCT05006287	Oct 2022 → May 2024	atrial fibrillation	St. Paul's Hospital, Canada	Unknown	No outcome recorded
Phase 2	NCT05033964	Dec 2021 → Dec 2022 overdue	coronary artery disorder	Elixir Medical Corporation	Active not recruiting	No outcome recorded
Phase 2	NCT05233124	Sep 2021 → Jun 2023	acute coronary syndrome, vascular ectasia	Instituto Nacional de Cardiologia Ignacio Chavez	Unknown	Missed primary
Phase 2	NCT03684564	Jul 2021 → Jul 2025	antiphospholipid syndrome, brain ischemia, ischemic stroke, systemic lupus erythematosus	University College, London	Completed	No outcome recorded
Phase 2	NCT04416048	Nov 2020 → Jul 2021	COVID-19	Charite University, Berlin, Germany	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04504032	Sep 2020 → Mar 2021	COVID-19	Gates Medical Research Institute	Terminated	No outcome recorded
Phase 2	NCT03178864	Mar 2019 → Oct 2022	cerebral sinovenous thrombosis	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT03310021	Aug 2017 → Aug 2019	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03139487	Aug 2017 → Sep 2021	ampulla of vater cancer, esophageal cancer, gastric cancer, gastroesophageal cancer +3	Asan Medical Center	Unknown	No outcome recorded
Phase 2	NCT02998905	Apr 2017 → Oct 2019	atrial fibrillation, intracerebral hemorrhage	Population Health Research Institute	Completed	No outcome recorded
Phase 2	NCT02293395	Apr 2015 → Oct 2016	acute coronary syndrome	Janssen Research & Development, LLC	Completed	Missed primary
Phase 2	NCT02309411	Jan 2015 → Apr 2017	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT02260622	Oct 2014 → Jun 2017	limb ischemia	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT02271399	Oct 2014 → Jan 2016	venous thromboembolism	Hanyang University Seoul Hospital	Completed	No outcome recorded
Phase 2	NCT02072668	Feb 2014 → Oct 2018	sickle cell disease, sickle cell-beta zero-thalassemia	University of North Carolina, Chapel Hill	Completed	Missed primary
Phase 2	NCT02042534	Jan 2014 → Dec 2015	transient ischemic attack	Asan Medical Center	Completed	Missed primary
Phase 2	NCT01684423	Feb 2013 → Sep 2016	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT02128841	Sep 2012 → Sep 2017	aortic valve disorder, cardiac valvular defect	Insel Gruppe AG, University Hospital Bern	Terminated	No outcome recorded
Phase 2	NCT01629381	May 2012 → Mar 2014	hemorrhagic disease, venous thromboembolism	University of Padova	Completed	Met primary
Phase 2	NCT01442792	Oct 2011 → Jan 2013	coronary artery disorder	Bayer	Completed	No outcome recorded
Phase 2	NCT00786422	May 2009 → May 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00402597	Nov 2006 → Oct 2008	acute coronary syndrome	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	Missed primary
Phase 2	NCT00973245	Jul 2006 → Jan 2007	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00973323	Sep 2005 → Mar 2006	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00395772	Dec 2004 → Dec 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00396786	Nov 2004 → Jul 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00779064	Jul 2004 → Jun 2005	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00839163	Mar 2004 → Oct 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00402467	Feb → Nov 2004	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00398905	Jan → Sep 2004	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00839826	Dec 2002 → Nov 2003	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 2/38 trials · 2 met primary
Phase 2/3	NCT06965998	Aug 2025 → Aug 2026 overdue	thrombophlebitis, thrombotic disease	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 2/3	NCT05920343	Nov 2024 → Oct 2026 expected	malignant urinary system neoplasm, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 2/3	NCT05700266	Dec 2023 → Dec 2024	intracranial arteriosclerosis, ischemic stroke	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
Phase 2/3	NCT04273516	Aug 2020 → Apr 2023	ischemic stroke	Mazandaran University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT04351724	Apr 2020 → Dec 2021	COVID-19	Medical University of Vienna	Unknown	Met primary
Phase 2/3	NCT03428373	Jan 2019 → Dec 2023	plasma cell myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
Phase 2/3	NCT03273322	Sep 2017 → Nov 2018	atrial fibrillation, hemorrhagic disease	Assistance Publique - Hôpitaux de Paris	Completed	Met primary
Phase 2/3	NCT01923818	Sep 2013 → Sep 2015	transient ischemic attack	Xijing Hospital	Unknown	No outcome recorded
Phase 397 trials · 18 met primary · 19 missed
Phase 3	NCT07468448	Sep 2026 → Dec 2029 expected	cerebral atherosclerosis, ischemic stroke	Population Health Research Institute	Not yet recruiting	No outcome recorded
Phase 3	NCT07318610	Jul 2026 → Aug 2029 expected	peripheral arterial disease	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT07202897	Jan 2026 → Jan 2032 expected	hypertrophic cardiomyopathy	Rennes University Hospital	Recruiting	No outcome recorded
Phase 3	NCT07456085	Nov 2025 → Apr 2027 expected	heart valve disorder	Rawalpindi Institute of Cardiology	Enrolling by invitation	No outcome recorded
Phase 3	NCT06580223	Sep 2025 → Sep 2027 expected	plasma cell myeloma, venous thromboembolism	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Not yet recruiting	No outcome recorded
Phase 3	NCT06780462	Jun 2025 → Dec 2027 expected	Behcet disease	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05410275	Jan 2025 → Jan 2027 expected	chronic kidney disease	University Hospital, Tours	Recruiting	No outcome recorded
Phase 3	NCT06611319	Nov 2024 → Mar 2027 expected	osteoarthritis, hip, venous thromboembolism	Prof. Stavros Konstantinides, MD	Recruiting	No outcome recorded
Phase 3	NCT06195540	Jul 2024 → Nov 2028 expected	pulmonary embolism, venous thromboembolism	University Hospital, Angers	Recruiting	No outcome recorded
Phase 3	NCT05387954	Jul 2023 → Jul 2031 expected	ischemic stroke, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05825573	May 2023 → Feb 2025 overdue	ST-elevation myocardial infarction, heart failure, thrombotic disease	Nîmes University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT05029063	Oct 2022 → Dec 2026 expected	cancer, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 3	NCT05047172	Aug 2022 → Jan 2027 expected	intracranial arteriosclerosis, stroke disorder	University of Florida	Active not recruiting	No outcome recorded
Phase 3	NCT05198960	Jul 2022 → Jul 2027 expected	acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis	University Hospital, Brest	Recruiting	No outcome recorded
Phase 3	NCT05033314	Jun 2022 → Oct 2024	sickle cell disease, venous thromboembolism	University Health Network, Toronto	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02832531	Jan → Apr 2022	rheumatic heart disease	Population Health Research Institute	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT05035277	Dec 2021 → Jun 2026	aortic valve stenosis	Oslo University Hospital	Completed	No outcome recorded
Phase 3	NCT05077683	Oct 2021 → Mar 2023	acute myocardial infarction, thrombotic disease	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT04967573	Aug 2021 → Jun 2023	venous thromboembolism	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 3	NCT03969953	Jan 2021 → Oct 2025	cardiovascular disorder, end stage renal failure	The George Institute	Completed	Missed primary
Phase 3	NCT04999176	Oct 2020 → Jul 2024	cancer, venous thromboembolism	André Luiz Malavasi Longo de Oliveira	Unknown	No outcome recorded
Phase 3	NCT04662684	Oct 2020 → Jul 2021	COVID-19, venous thromboembolism	Science Valley Research Institute	Completed	No outcome recorded
Phase 3	NCT04508023	Aug 2020 → Jun 2022	COVID-19	Janssen Research & Development, LLC	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT05705089	Jul 2020 → Feb 2023	ST-elevation myocardial infarction, thrombotic disease	Rajaie Cardiovascular Medical and Research Center	Completed	Missed primary
Phase 3	NCT04067505	May 2020 → Dec 2024	May-Thurner syndrome	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 3	NCT04066764	May 2020 → Oct 2024	venous thromboembolism	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 3	NCT04324463	Apr 2020 → Dec 2022	severe acute respiratory syndrome	Population Health Research Institute	Completed	Missed primary
Phase 3	NCT04309240	Mar 2020 → Mar 2022	cancer, venous thromboembolism	LiuZhou People's Hospital	Unknown	No outcome recorded
Phase 3	NCT04142125	Feb 2020 → Sep 2023	intracranial arterial disease, ischemic stroke	Population Health Research Institute	Completed	Missed primary
Phase 3	NCT03764241	Feb 2020 → Mar 2022	ST-elevation myocardial infarction, thrombotic disease	RenJi Hospital	Unknown	No outcome recorded
Phase 3	NCT04045665	Dec 2019 → Aug 2026 overdue	atrial fibrillation, hemorrhagic disease, stroke disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 3	NCT03996772	Jun 2019 → May 2024	atrial fibrillation, intracerebral hemorrhage	Imperial College London	Completed	Mixed
Phase 3	NCT03926156	May 2019 → May 2021	atrial fibrillation, mitral valve stenosis, rheumatic heart disease	Rajaie Cardiovascular Medical and Research Center	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03702582	Apr 2019 → Oct 2023	atrial fibrillation, hemorrhagic disease, stroke disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT03786757	Apr 2019 → Mar 2022	ST-elevation myocardial infarction, thrombotic disease	RenJi Hospital	Unknown	No outcome recorded
Phase 3	NCT03506815	Mar 2019 → May 2020	cancer, venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 3	NCT03605433	Dec 2018 → Dec 2019	coronary artery disorder	Unidade Local de Saúde de Coimbra, EPE	Unknown	No outcome recorded
Phase 3	NCT03926780	Dec 2018 → May 2020	hyperheparinemia, thrombotic disease	The Young Investigator Group of Cardiovascular Research	Completed	No outcome recorded
Phase 3	NCT03331484	Nov 2018 → Jul 2023	acute coronary syndrome, atrial fibrillation	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT03630055	Oct 2018 → Jun 2025	arterial occlusion	Ottawa Heart Institute Research Corporation	Terminated	No outcome recorded
Phase 3	NCT03153150	Mar 2018 → Mar 2021	atrial fibrillation, atrial flutter, intracerebral hemorrhage, subarachnoid hemorrhage	University of Edinburgh	Completed	Missed primary
Phase 3	NCT03285438	Nov 2017 → Nov 2023	venous thromboembolism	University Hospital, Brest	Completed	Missed primary
Phase 3	NCT04569279	Sep 2017 → Mar 2020	cerebral sinovenous thrombosis	Damascus University	Completed	No outcome recorded
Phase 3	NCT03181386	May 2017 → Nov 2020	atrial fibrillation, hemorrhagic disease, periodontal disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 3	NCT03055026	May 2017 → Jul 2021	venous thromboembolism	Fadoi Foundation, Italy	Completed	Met primary
Phase 3	NCT03299296	Jan 2017 → Jan 2018	venous thromboembolism	Ahmed AbdelMoneim Hassan Ali	Unknown	No outcome recorded
Phase 3	NCT02846532	Nov 2016 → Jul 2020	thrombotic disease	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02664155	Oct 2016 → Nov 2021	impaired renal function disease	University Hospital of Saint-Etienne	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02746185	Sep 2016 → Apr 2018	neoplasm, venous thromboembolism	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT02832544	Aug 2016 → Aug 2022	rheumatic heart disease	Population Health Research Institute	Completed	Missed primary
Phase 3	NCT02643212	May 2016 → Dec 2019	cirrhosis of liver	David Garcia Cinca	Unknown	Missed primary
Phase 3	NCT02833948	May 2016 → Dec 2018	aortic valve stenosis, cardiac valvular defect, thrombotic disease	ECRI bv	Completed	Met primary
Phase 3	NCT02583191	Mar 2016 → Jun 2019	cancer, venous thromboembolism	AIO-Studien-gGmbH	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02556203	Dec 2015 → Nov 2018	—	Bayer	Terminated	Missed primary
Phase 3	NCT02401594	Dec 2015 → Apr 2018	—	University Hospital of Saint-Etienne	Terminated	Met primary
Phase 3	NCT02627053	Dec 2015 → Jun 2019	isolated mesenteric vein thrombosis, isolated splenic vein thrombosis, portal vein thrombosis	University of Insubria	Unknown	No outcome recorded
Phase 3	NCT02544932	Oct 2015 → Sep 2017	atrial fibrillation	Kyunghee University Medical Center	Unknown	No outcome recorded
Phase 3	NCT02555878	Sep 2015 → Aug 2018	neoplasm	Janssen Research & Development, LLC	Completed	Missed primary
Phase 3	NCT02555111	Sep 2015 → Feb 2020	portal vein thrombosis, venous thromboembolism	Assistance Publique - Hôpitaux de Paris	Completed	Met primary
Phase 3	NCT02504216	Aug 2015 → Nov 2019	peripheral arterial disease	Bayer	Completed	Met primary
Phase 3	NCT02164578	Apr 2015 → Dec 2018	diabetes mellitus, noninsulin-dependent, 2	GWT-TUD GmbH	Completed	No outcome recorded
Phase 3	NCT02486445	Mar 2015 → Nov 2018	venous thromboembolism	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 3	NCT02313909	Dec 2014 → Feb 2018	stroke disorder	Bayer	Terminated	Missed primary
Phase 3	NCT02157272	Dec 2014 → Jan 2018	antiphospholipid syndrome	University of Padova	Terminated	Missed primary
Phase 3	NCT02234843	Nov 2014 → Jan 2019	venous thromboembolism	Bayer	Completed	Missed primary
Phase 3	NCT02123524	Nov 2014 → Dec 2018	thrombophlebitis	McMaster University	Completed	No outcome recorded
Phase 3	NCT03193502	May 2014 → Jul 2020	portal vein thrombosis	Tanta University	Unknown	No outcome recorded
Phase 3	NCT02064439	Mar 2014 → Sep 2016	pulmonary embolism, venous thromboembolism	Bayer	Completed	Mixed
Phase 3	NCT02111564	Jan 2014 → Mar 2018	heart failure, infectious disease, respiratory failure, rheumatic disorder +1	Janssen Research & Development, LLC	Completed	Missed primary
Phase 3	NCT01877915	Sep 2013 → Apr 2018	coronary artery disorder, heart failure	Janssen Research & Development, LLC	Completed	Missed primary
Phase 3	NCT01839357	Aug 2013 → Nov 2014	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 3	NCT01830543	May 2013 → Jul 2016	atrial fibrillation	Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 3	NCT02926170	Mar 2013 → Dec 2017	antiphospholipid syndrome	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
Phase 3	NCT01776424	Feb 2013 → Jul 2017	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01720108	Feb 2013 → Jul 2016	venous thromboembolism	David Anderson	Completed	No outcome recorded
Phase 3	NCT01729871	Feb 2013 → Oct 2014	atrial fibrillation	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT01675076	Jan 2013 → Oct 2017	—	Ottawa Heart Institute Research Corporation	Completed	Missed primary
Phase 3	NCT01598168	Jan 2013 → Jul 2015	heparin-induced thrombocytopenia	McMaster University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01674647	Oct 2012 → Jan 2014	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 3	NCT01499953	Apr 2012 → May 2016	thrombophlebitis	GWT-TUD GmbH	Completed	Met primary
Phase 3	NCT01516840	Mar 2012 → Dec 2013	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01516814	Feb 2012 → Oct 2013	pulmonary embolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01206972	Oct 2010 → May 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01205932	Sep 2010 → Jun 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01094886	Mar → Dec 2010	osteoarthritis, hip, osteoarthritis, knee, venous thromboembolism	Ortho-McNeil Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT00809965	Nov 2008 → Sep 2011	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	Met primary
Phase 3	NCT00571649	Dec 2007 → Aug 2010	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00562289	Dec 2007 → Dec 2016	atrial septal aneurysm, ischemic stroke, migraine disorder, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Completed	Met primary
Phase 3	NCT00494871	Jun 2007 → Dec 2009	atrial fibrillation	Bayer	Completed	Met primary
Phase 3	NCT00440193	Mar 2007 → Apr 2010	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00439777	Mar 2007 → Sep 2011	pulmonary embolism	Bayer	Completed	Met primary
Phase 3	NCT00439725	Feb 2007 → Aug 2009	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00403767	Dec 2006 → Sep 2010	atrial fibrillation, stroke disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	Mixed
Phase 3	NCT00362232	Jun 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00332020	Feb 2006 → May 2007	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00329628	Feb 2006 → Mar 2007	venous thromboembolism	Bayer	Completed	Met primary
Phase 3	NCT00361894	Feb 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	Met primary

Phase 473 trials · 7 met primary · 2 missed
Phase 4	NCT07609654	Jun 2026 → Jun 2029 expected	atrial fibrillation, intracerebral hemorrhage, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT07511257	Feb 2026 → Jun 2029 expected	ST-elevation myocardial infarction, acute coronary syndrome, vascular ectasia	Instituto Nacional de Cardiologia Ignacio Chavez	Recruiting	No outcome recorded
Phase 4	NCT07195812	Oct 2025 → May 2028 expected	ST-elevation myocardial infarction	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT06901466	Jun 2025 → Oct 2027 expected	mitral valve insufficiency	Chinese Academy of Medical Sciences, Fuwai Hospital	Recruiting	No outcome recorded
Phase 4	NCT05643651	Jun 2025 → Jun 2027 expected	Kawasaki disease, coronary aneurysm	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT06812455	Mar 2025 → Mar 2028 expected	arterial occlusion	AHEPA University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06108414	Sep 2024 → Dec 2026 expected	atrial fibrillation, stroke disorder	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 4	NCT07618988	Aug 2024 → Dec 2025	venous thromboembolism	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT06476301	Aug 2024 → Feb 2026 overdue	—	RenJi Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06401616	May 2024 → Mar 2028 expected	atrial fibrillation	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06013020	Apr 2024 → Dec 2026 expected	ST-elevation myocardial infarction	Zunyi Medical College	Recruiting	No outcome recorded
Phase 4	NCT06873321	Feb 2024 → Jul 2025 overdue	peripheral arterial disease, venous thromboembolism	Science Valley Research Institute	Recruiting	No outcome recorded
Phase 4	NCT05735639	Jan 2024 → Jun 2027 expected	varicose disease, venous thromboembolism	Imperial College London	Recruiting	No outcome recorded
Phase 4	NCT06978439	Jan 2024 → Dec 2025 overdue	Kawasaki disease, coronary aneurysm	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT07404436	Jan 2024 → Dec 2026 expected	idiopathic membranous glomerulonephritis	Beijing Friendship Hospital	Recruiting	No outcome recorded
Phase 4	NCT06103266	Jan 2024 → Jun 2025	atrial fibrillation, coronary artery disorder	J.P.S Henriques	Unknown	No outcome recorded
Phase 4	NCT05638867	Nov 2023 → Dec 2026 expected	acute coronary syndrome, coronary artery disorder	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 4	NCT07796217	Nov 2023 → Jun 2027 expected	coronary artery disorder, hemorrhagic disease, peripheral arterial disease	Seoul National University Bundang Hospital	Recruiting	No outcome recorded
Phase 4	NCT06314763	Nov 2023 → Mar 2024	—	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT05794399	Jun 2023 → Mar 2026 overdue	myocardial infarction, thrombotic disease	Shahid Gangalal National Heart Centre	Recruiting	No outcome recorded
Phase 4	NCT05973188	May 2023 → Jun 2024	thrombotic disease	Peshawar Institute of Cardiology	Unknown	No outcome recorded
Phase 4	NCT05487950	Apr 2023 → Apr 2027 expected	cardiac rhythm disease	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 4	NCT06187311	Jan 2023 → Jun 2026 overdue	atrial fibrillation	Korea University Anam Hospital	Recruiting	No outcome recorded
Phase 4	NCT04135677	Nov 2022 → Oct 2024	stroke disorder, thrombotic disease	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 4	NCT05573958	Oct 2022 → Mar 2023	acute coronary syndrome	Sarmad Zahoor	Unknown	No outcome recorded
Phase 4	NCT05303818	Jun 2022 → Jun 2023	colorectal cancer, venous thromboembolism	Hospital do Servidor Publico Estadual	Unknown	No outcome recorded
Phase 4	NCT05009862	Apr 2022 → Jul 2025	peripheral arterial disease	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT05210725	Mar → Apr 2022	coronary artery disorder	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT04258488	Feb 2022 → Dec 2027 expected	aortic valve disorder, thrombotic disease	Joon Bum Kim	Recruiting	No outcome recorded
Phase 4	NCT05671276	Feb 2022 → Sep 2024	atrial fibrillation, intracranial embolism	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
Phase 4	NCT05292846	Jan 2022 → Feb 2024	coronary artery disorder, hemorrhagic disease	Hospital Universitario La Fe	Unknown	Met primary
Phase 4	NCT04990791	Aug 2021 → Aug 2023	coronary artery disorder	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT05797376	Aug 2021 → Nov 2024	atherosclerosis, carotid stenosis, coronary artery disorder, peripheral arterial disease	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT04970576	Jun 2021 → May 2024	acute coronary syndrome, thrombotic disease	National Institute of Cardiovascular Diseases, Pakistan	Completed	No outcome recorded
Phase 4	NCT04700826	Jun 2021 → Dec 2027 expected	atrial fibrillation	University of Birmingham	Recruiting	No outcome recorded
Phase 4	NCT04853719	Apr 2021 → Nov 2022	intermittent vascular claudication, peripheral arterial disease	Science Valley Research Institute	Completed	Met primary
Phase 4	NCT04805710	Mar 2021 → Sep 2022	—	Shenyang Northern Hospital	Unknown	No outcome recorded
Phase 4	NCT04619927	Mar 2021 → Jun 2024	peripheral arterial disease	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT06019741	Feb 2021 → May 2022	postoperative ventricular dysfunction	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT05300555	Jan 2021 → Jan 2022	atrial fibrillation	University of Sao Paulo General Hospital	Unknown	No outcome recorded
Phase 4	NCT04715295	Oct 2020 → May 2021	COVID-19	Yaounde Central Hospital	Unknown	No outcome recorded
Phase 4	NCT04437654	Jul 2020 → Aug 2025	—	Yonsei University	Completed	No outcome recorded
Phase 4	NCT04394377	Jun 2020 → Mar 2021	COVID-19	Brazilian Clinical Research Institute	Completed	Missed primary
Phase 4	NCT04218656	Jun 2020 → Dec 2021	peripheral arterial disease	Radboud University Medical Center	Completed	Missed primary
Phase 4	NCT04256525	May 2020 → Aug 2021	venous thromboembolism	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT04073316	Feb 2020 → Feb 2023	atrial fibrillation	University Hospital, Angers	Unknown	No outcome recorded
Phase 4	NCT04059679	Jan 2020 → Mar 2021	coronary artery disorder, peripheral arterial disease	LifeBridge Health	Unknown	No outcome recorded
Phase 4	NCT04006288	Sep 2019 → Jan 2022	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT03968393	Jun 2019 → Dec 2028 expected	atrial fibrillation, stroke disorder	Population Health Research Institute	Recruiting	No outcome recorded
Phase 4	NCT03718429	Jan 2019 → Feb 2020	atrial fibrillation, coronary artery disorder, peripheral arterial disease	University of Florida	Completed	Mixed
Phase 4	NCT03775746	Jan 2019 → Dec 2021	acute coronary syndrome	East and North Hertfordshire NHS Trust	Unknown	No outcome recorded
Phase 4	NCT03749057	Nov 2018 → Mar 2025	cerebral infarction, transient ischemic attack	General Hospital of Shenyang Military Region	Completed	No outcome recorded
Phase 4	NCT03490994	Apr 2018 → Sep 2019	heart failure	Yonsei University	Unknown	No outcome recorded
Phase 4	NCT07699796	Mar 2018 → Nov 2020	chronic venous insufficiency, varicose disease, venous thromboembolism	Heart, Artery, and Vein Center of Fresno	Completed	No outcome recorded
Phase 4	NCT03363035	Jan 2018 → Nov 2021	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Second Xiangya Hospital of Central South University	Completed	Mixed
Phase 4	NCT02970773	Dec 2017 → Dec 2018	spinal cord injury, thrombotic disease	Swiss Paraplegic Research, Nottwil	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03799822	May 2017 → Sep 2020	atrial fibrillation	Onze Lieve Vrouw Hospital	Completed	Met primary
Phase 4	NCT02666742	Feb 2017 → May 2020	stroke disorder, ventricular tachycardia	Kansas City Heart Rhythm Institute	Completed	Met primary
Phase 4	NCT03673605	Dec 2016 → Oct 2017	atrial fibrillation, mitral valve stenosis	PharmEvo Pvt Ltd	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT02810704	Dec 2016 → Sep 2025	pulmonary embolism, venous thromboembolism	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 4	NCT02584660	Oct 2015 → Mar 2017	pulmonary embolism	Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 4	NCT02426944	Oct 2015 → Jul 2019	atrial fibrillation	Charles University, Czech Republic	Completed	Met primary
Phase 4	NCT02506985	Jul 2015 → Jun 2016	pulmonary embolism, venous thromboembolism	Susan Smyth	Terminated	No outcome recorded
Phase 4	NCT02642419	Jan 2015 → Dec 2017	atrial fibrillation	Japan Cardiovascular Research Foundation	Unknown	Met primary
Phase 4	NCT02116036	Sep 2014 → Sep 2017	antiphospholipid syndrome	St. Joseph's Healthcare Hamilton	Completed	No outcome recorded
Phase 4	NCT01989845	Oct 2013 → Dec 2016	blood coagulation disease, hemorrhagic disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT02047006	Sep 2013 → Feb 2014	chronic renal failure syndrome	AZ Sint-Jan AV	Completed	No outcome recorded
Phase 4	NCT02334254	Aug 2013 → Jan 2016	atrial fibrillation	Beijing Anzhen Hospital	Unknown	No outcome recorded
Phase 4	NCT02066662	Jul 2013 → Mar 2020	arterial disorder	RWTH Aachen University	Completed	No outcome recorded
Phase 4	NCT02161965	May 2013 → Dec 2016	atrial fibrillation, pulmonary embolism, venous thromboembolism	University Hospital, Angers	Completed	No outcome recorded
Phase 4	NCT01708850	Nov 2012 → May 2016	neoplasm, venous thromboembolism	London Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT01706146	Oct 2012 → Feb 2015	atrial fibrillation	Northwestern University	Completed	No outcome recorded
Phase 4	NCT01210755	Nov 2010 → Mar 2011	venous thromboembolism	University Hospital, Grenoble	Completed	No outcome recorded

Phase not applicable33 trials · 1 met primary
—	NCT07869615	Sep 2026 → Apr 2027 expected	—	Military Hospital of Tunis	Recruiting	No outcome recorded
—	NCT07583784	Aug 2026 → Dec 2031 expected	ST-elevation myocardial infarction, atrial fibrillation	Chonnam National University Hospital	Recruiting	No outcome recorded
—	NCT07602062	Jun 2026 → Dec 2027 expected	esophageal varices with bleeding, portal vein thrombosis	Shanghai Zhongshan Hospital	Not yet recruiting	No outcome recorded
—	NCT07820670	Dec 2025 → Jun 2027 expected	venous thromboembolism	Wolfson Medical Center	Recruiting	No outcome recorded
—	NCT07613840	Apr 2025 → Apr 2027 expected	peripheral arterial disease, thrombotic disease	Massachusetts General Hospital	Recruiting	No outcome recorded
—	NCT07270263	Nov 2024 → Apr 2026 overdue	leukemia, lymphoma, pulmonary embolism, venous thromboembolism	Medical University of Gdansk	Recruiting	No outcome recorded
—	NCT06689241	Oct 2024 → Dec 2025 overdue	morbid obesity	Alexandria University	Recruiting	No outcome recorded
—	NCT06216769	Feb 2024 → Dec 2030 expected	atrial fibrillation	Seoul National University Hospital	Recruiting	No outcome recorded
—	NCT07523347	Dec 2023 → Dec 2025	cerebral sinovenous thrombosis	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT06196918	Nov 2023 → Aug 2024	malignant glioma	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
—	NCT06057467	Sep 2023 → Oct 2025	atrial fibrillation, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT05960721	Jul 2023 → Jul 2025 overdue	atrial fibrillation	Xijing Hospital	Recruiting	No outcome recorded
—	NCT05892042	May 2023 → Sep 2026 overdue	ST-elevation myocardial infarction, thrombotic disease	Jilin University	Recruiting	No outcome recorded
—	NCT05750758	Feb → Aug 2023	acute coronary syndrome	Henan Institute of Cardiovascular Epidemiology	Completed	No outcome recorded
—	NCT05449327	Feb 2023 → Sep 2025	venous thromboembolism	Chiayi Christian Hospital	Completed	No outcome recorded
—	NCT05546957	Jan → Apr 2023	—	Regeneron Pharmaceuticals	Completed	No outcome recorded
—	NCT05353140	Sep 2022 → Sep 2028 expected	atrial fibrillation	Xijing Hospital	Recruiting	No outcome recorded
—	NCT04694248	Nov 2021 → Dec 2026 expected	May-Thurner syndrome, iliac vein thrombophlebitis, venous thromboembolism	First Affiliated Hospital of Zhejiang University	Recruiting	No outcome recorded
—	NCT04935515	Apr → May 2021	COVID-19	Manimarane Arjunan, MD,DM (Cardiology)	Completed	No outcome recorded
—	NCT04486859	Dec 2020 → May 2025 overdue	Cushing disease due to pituitary adenoma, pulmonary embolism, venous thromboembolism	Huashan Hospital	Active not recruiting	No outcome recorded
—	NCT04970381	Sep 2020 → Oct 2022	thrombotic disease	China National Center for Cardiovascular Diseases	Completed	No outcome recorded
—	NCT05801068	Aug 2020 → May 2024 overdue	atrial fibrillation, hemorrhagic disease	Seoul National University Hospital	Active not recruiting	No outcome recorded
—	NCT04333407	Apr 2020 → Nov 2021	COVID-19	Imperial College London	Terminated	No outcome recorded Stop: Enrollment
—	NCT03759938	Jun 2019 → May 2024	atrial fibrillation, ischemic stroke	University College, London	Unknown	Met primary
—	NCT03792152	Jun 2019 → Jan 2022	atrial fibrillation	The Second Affiliated Hospital of Chongqing Medical University	Unknown	No outcome recorded
—	NCT03642509	Jan 2019 → Jan 2026 overdue	atrial fibrillation, stroke disorder	University of Aarhus	Recruiting	No outcome recorded
—	NCT03148457	Nov 2017 → Dec 2022	ischemic stroke	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
—	NCT03277001	Oct 2017 → Jul 2019	chronic obstructive pulmonary disease, venous thromboembolism	Huashan Hospital	Unknown	No outcome recorded
—	NCT03005444	Jun 2017 → Dec 2023	cirrhosis of liver	Air Force Military Medical University, China	Unknown	No outcome recorded
—	NCT03804697	Aug 2016 → Aug 2017	venous thromboembolism	Guangdong Provincial People's Hospital	Completed	No outcome recorded
—	NCT02504177	Jun 2015 → Jun 2019	atrial fibrillation	Yonsei University	Unknown	No outcome recorded
—	NCT01986192	Nov 2013 → Feb 2015	venous thromboembolism	Seoul National University Hospital	Unknown	No outcome recorded
—	NCT02085824	Jul 2012 → Apr 2014	osteoarthritis, hip	Centre of Postgraduate Medical Education	Unknown	No outcome recorded

Phase not stated1 trial
—	NCT02894307	—	cardiac valvular defect	Hospital Ana Nery	No longer available	No outcome recorded
Comparator or background therapy111 trials
Phase 0	NCT07832578 Comparator	Jun → Dec 2026 expected	limb ischemia	King Edward Medical University	Recruiting	No outcome recorded
Phase 0	NCT06615596 Comparator	Aug 2025 → Jan 2029 expected	atrial fibrillation	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 0	NCT07032025 Comparator	Jul 2025 → Jul 2027 expected	pulmonary embolism	RenJi Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT06145269 Comparator	Dec 2023 → Apr 2025	venous thromboembolism	Assiut University	Unknown	No outcome recorded
Phase 0	NCT02331095 Background	Jan 2015 → Oct 2017	venous thromboembolism	Ohio State University	Terminated	Missed primary Stop: Enrollment
Show all 111 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 96

Date	Issuer	Release
2025-09-30	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension lupin.com ↗
2025-05-15	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg lupin.com ↗
2025-05-01	Alembic Pharmaceuticals Ltd.	Regulatory 15th May, 2025 Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg.
2025-03-07	Lupin Limited	Regulatory Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States lupin.com ↗ Mumbai, Naples, March 07, 2025: Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.
2024-04-08	Janssen Research & Development, LLC	Results Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization jnj.com ↗ Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO®(rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.
2024-04-08	Janssen Research & Development, LLC	Results Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization jnj.com ↗ Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
2024-03-25	Bristol-Myers Squibb	Results Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio bms.com ↗ those who received ELIQUIS had a statistically significant lower risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those patients who received rivaroxaban
2024-01-23	Lupin Limited	Regulatory Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP lupin.com ↗ Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA)
2024-01-01	Alembic Pharmaceuticals Ltd.	Regulatory Press Release USFDA Products Approvals For the Qtr ended 31st Dec, 2023 alembicpharmaceuticals.com ↗
2023-11-14	Janssen Research & Development, LLC	Results New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD) jnj.com ↗ Data from the two analyses demonstrate the role of XARELTO® in treating both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD).
2023-08-25	Bristol-Myers Squibb	Results Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 bms.com ↗ Switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those who continued Eliquis
2023-03-06	Bayer	Results New real world study data on reduced risk of adverse kidney outcomes for Xarelto™ compared to VKA bayer.com ↗ In the XARENO study, Xarelto (rivaroxaban) was associated with a reduced risk of adverse kidney outcomes in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD) compared to vitamin K antagonists.
2023-03-05	Janssen Research & Development, LLC	Results New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER) jnj.com ↗ This analysis of the VOYAGER PAD study showed XARELTO®plus aspirin resulted in a 33 percent reduction in acute limb ischemia and a 15 percent reduction in major adverse limb and cardiovascular events, with or without dual antiplatelet therapy (DAPT).
2022-12-09	Janssen Research & Development, LLC	Results Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients jnj.com ↗ Data from the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) found XARELTO®showed non-inferiority for the composite outcome of recurrent VTE or any bleeding resulting in hospitalization for treatment of patients with CAT.
2022-06-21	Bayer	Regulatory Rivaroxaban (Xarelto™) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation bayer.com ↗ The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization.
2022-05-23	Janssen Research & Development, LLC	Results New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) jnj.com ↗ Separately, the XATOA registry provides real-world evidence of the benefit of DPI with the XARELTO®vascular dose in patients with CAD and/or PAD.
2022-05-23	Janssen Research & Development, LLC	Results New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) jnj.com ↗ These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in patients with CAD and/or PAD.
2022-05-23	Bayer	Results Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease bayer.com ↗ Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD)
2022-04-04	Bayer	Results XARENO study revealed Xarelto™ was associated with net clinical benefit and a reduced risk of kidney failure compared to vitamin K antagonists bayer.com ↗
2022-04-01	Janssen Research & Development, LLC	Results Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions jnj.com ↗ Data from the two analyses demonstrate the role that the XARELTO®vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and without a history of statin therapy.
2021-12-21	Janssen Research & Development, LLC	Regulatory FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients jnj.com ↗ #BREAKINGNEWS: @US_FDA approves @JanssenUS therapy for the treatment and prevention of #bloodclots in #pediatric patients, providing an alternative to injectable anticoagulants that have long been the standard of care.
2021-12-21	Bayer	Regulatory U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children bayer.com ↗
2021-12-20	Janssen Research & Development, LLC	Regulatory FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have undergone the Fontan procedure.
2021-10-04	Norgine	Results New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients norgine.com ↗ Ciraparantag produced a rapid and dose-related reversal of anticoagulation induced by apixaban and rivaroxaban compared with placebo in 2 dose ranging studies in healthy elderly adults (age 50-75 years).
2021-10-04	Covis Pharma S.à.r.l.	Results New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients covispharma.com ↗ Ciraparantag produced a rapid and dose-related reversal of anticoagulation induced by apixaban and rivaroxaban compared with placebo in two dose ranging studies in healthy elderly adults (age 50-75 years).
2021-09-27	Janssen Research & Development, LLC	Results New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events jnj.com ↗ also found treatment with XARELTO®was associated with a similar safety profile compared to aspirin.
2021-09-27	Janssen Research & Development, LLC	Results New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events jnj.com ↗ New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
2021-09-27	Bayer	Results New data for rivaroxaban in patients following the Fontan procedure and at risk for blood clots and blood clot related events bayer.com ↗ A comparable and low prevalence of bleeding events in both treatment arms was observed.
2021-08-24	Janssen Research & Development, LLC	Regulatory FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD jnj.com ↗
2021-08-24	Janssen Research & Development, LLC	Regulatory FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD.
2021-08-24	Bayer	Regulatory U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin bayer.com ↗ The U.S. Food and Drug Administration (FDA) has approved an expansion of the peripheral artery disease (PAD) indication for the Xarelto™ (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD.
2021-06-23	Janssen Research & Development, LLC	Regulatory Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO®(rivaroxaban) in pediatric patients.
2021-06-23	Janssen Research & Development, LLC	Regulatory Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients.
2021-06-23	Bayer	Regulatory Rivaroxaban application submitted to U.S. FDA for approval to treat VTE and to prevent VTE in children bayer.com ↗ Bayer´s development partner, Janssen Research & Development, LLC has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of the oral anticoagulant Xarelto™ (rivaroxaban) in pediatric patients.
2021-05-17	Bayer	Results Large real-world study shows benefit of rivaroxaban in patients with nonvalvular atrial fibrillation with type 2 diabetes bayer.com ↗ Real-world data presented at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21) showed that the oral Factor Xa inhibitor rivaroxaban (Xarelto™) was associated with reduced vascular mortality in patients with nonvalvular atrial fibrillation (NVAF) and comorbid type 2 diabetes (T2D), with fewer bleeding-related hospitalizations versus warfarin.
2021-05-16	Janssen Research & Development, LLC	Results Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization jnj.com ↗ This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years.
2021-05-16	Janssen Research & Development, LLC	Results Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event.
2021-01-22	Bayer	Regulatory Japan approves rivaroxaban (XareltoTM) to treat children with venous thromboembolism (VTE) and to prevent recurrence bayer.com ↗ The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) to treat VTE and prevent VTE recurrence in children, including catheter related thrombosis, cerebral vein and sinus thrombosis.
2020-11-13	Bayer	Regulatory Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children bayer.com ↗ The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a marketing authorization extension of the oral Factor Xa inhibitor, rivaroxaban (Xarelto™).
2020-10-26	Janssen Research & Development, LLC	Regulatory Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO®(rivaroxaban) in patients with peripheral artery disease (PAD).
2020-10-26	Janssen Research & Development, LLC	Regulatory Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD).
2020-10-26	Bayer	Regulatory Rivaroxaban application submitted to U.S. FDA for new indication in patients after lower-extremity revascularization due to symptomatic PAD bayer.com ↗
2020-06-01	Alembic Pharmaceuticals Ltd.	Regulatory 22nd June, 2020, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited today announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets, 1 O mg, 15 mg, and 20 mg.
2020-03-29	Bayer	Results Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery bayer.com ↗ Bayer’s Factor Xa inhibitor, rivaroxaban (Xarelto™) reduced the risk of major venous thromboembolism (VTE) by about 75% in adult patients during a period of immobilization after nonmajor lower limb orthopaedic surgery, when compared to enoxaparin.
2020-03-28	Janssen Research & Development, LLC	Results Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization jnj.com ↗ VOYAGER PAD is the only study to show a significant benefit using dual pathway inhibition, an anticoagulant plus aspirin, in this patient population.
2020-03-28	Janssen Research & Development, LLC	Results Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization jnj.com ↗
2020-03-28	Bayer	Results Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization bayer.com ↗ In the Phase III VOYAGER PAD study Bayer´s Factor Xa inhibitor Xarelto™ (rivaroxaban) met its primary efficacy endpoint.
2019-11-25	Bayer	Regulatory Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism bayer.com ↗ Bayer has submitted an application to the European Medicines Agency (EMA) to extend the Xarelto marketing authorization, making it available for children up to 17 years old with confirmed VTE, including cerebral vein and sinus thrombosis.
2019-10-14	Janssen Research & Development, LLC	Regulatory U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients jnj.com ↗ With the approval of this new indication, XARELTO®can be initiated for these patients during hospitalization and continued after discharge for a total recommended duration of 31 to 39 days.
2019-10-14	Janssen Research & Development, LLC	Regulatory U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients jnj.com ↗ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
2019-10-14	Bayer	Regulatory U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients bayer.com ↗ Bayer AG and its development partner Janssen Research & Development, LLC announced today that the U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto™) for the prevention of venous thromboembolism (VTE), or blood clots, in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
2019-09-20	Janssen Research & Development, LLC	Results XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients jnj.com ↗ Notably, patients taking XARELTO®had significantly reduced healthcare resource utilization (HRU) and total medical costs compared to those taking warfarin.
2019-09-01	Bristol-Myers Squibb	Results Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation bms.com ↗ Results show Eliquis was associated with a lower rate of major bleeding and comparable rates of stroke and systemic thromboembolic events versus dabigatran or rivaroxaban
2019-07-08	Janssen Research & Development, LLC	Results XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study jnj.com ↗ These results from the largest pediatric study ever conducted for the treatment of VTE also show that the efficacy and safety profile of XARELTO®in a pediatric population with VTE is comparable to what has been observed in previous studies of adults with VTE.
2019-07-08	Bayer	Results Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism bayer.com ↗ Results from the phase III EINSTEIN-Jr. study showed a strong efficacy and safety profile of rivaroxaban in children with VTE, with results similar to those seen in previous studies in adults.
2019-04-29	Bayer	Results Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillation bayer.com ↗ The study demonstrated that in patients with atrial fibrillation and chronic kidney disease Xarelto delivered comparable effectiveness and better safety outcomes when compared to phenprocoumon.
2018-12-14	Janssen Research & Development, LLC	Regulatory Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients jnj.com ↗ Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
2018-11-11	Bristol-Myers Squibb	Results Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation bms.com ↗ Eliquis ® (apixaban) was associated with lower rates of stroke or systemic embolism and major bleeding in elderly patient populations when compared to rivaroxaban and dabigatran
2018-10-12	Bayer	Regulatory U.S. FDA approves Bayer’s Xarelto® for patients with coronary or peripheral artery disease bayer.com ↗ The U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto®), 2.5 mg twice daily, plus aspirin low dose once daily to reduce the risk of major cardiovascular events including cardiovascular (CV) death, heart attack or stroke in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
2018-08-27	Janssen Research & Development, LLC	Results XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study jnj.com ↗ XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
2018-08-27	Janssen Research & Development, LLC	Results Janssen Announces Results from MARINER and COMMANDER HF Studies jnj.com ↗ In both studies, there was no significant difference found between XARELTO® (rivaroxaban) and placebo for the primary efficacy endpoints.
2018-08-27	Bayer	Results Results of COMMANDER HF and MARINER studies with rivaroxaban published bayer.com ↗ Study results did not show a statistical difference in primary endpoints
2018-08-24	Bayer	Regulatory Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery disease bayer.com ↗
2018-07-27	Bayer	Regulatory Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease bayer.com ↗ The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a new indication of Bayer´s oral Factor Xa inhibitor Xarelto® (rivaroxaban).
2018-03-11	Bristol-Myers Squibb	Results Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants bms.com ↗ Eliquis ® (apixaban) use was associated with lower rates of stroke or systemic embolism and major bleeding than matched patients receiving rivaroxaban or dabigatran
2018-01-25	Boehringer Ingelheim	Results New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment prnewswire.com ↗
2018-01-16	Bayer	Results FDA report reaffirms safety profile and effectiveness of Bayer’s Xarelto® in routine clinical practice bayer.com ↗ Findings from the study - part of the active drug safety surveillance of the FDA - noted that a lower risk of ischemic stroke and intercranial haemorrhage was associated with the use of rivaroxaban compared to warfarin, whilst the risk of gastrointestinal bleeding was lower with warfarin.
2017-12-11	Janssen Research & Development, LLC	Regulatory Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD) jnj.com ↗ Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
2017-12-11	Bayer	Regulatory Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease bayer.com ↗ Bayer´s development partner, Janssen Research & Development, LLC has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the rivaroxaban (Xarelto®) vascular dose, 2.5 mg twice daily, to be used in combination with low dose aspirin.
2017-11-06	Bayer	Regulatory Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency bayer.com ↗ Bayer has submitted an application to the European Medicines Agency (EMA) for the marketing authorization of the vascular dose of its Factor Xa inhibitor rivaroxaban (Xarelto®) in combination with aspirin for the treatment of patients with coronary artery disease (CAD) or peripheral artery disease (PAD).
2017-10-30	Janssen Research & Development, LLC	Regulatory FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE) jnj.com ↗ Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of XARELTO® (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.
2017-10-30	Bayer	Regulatory Bayer receives FDA approval for Xarelto® 10 mg once daily for the extended treatment of venous thromboembolism bayer.com ↗ The FDA approval of the 10 mg dose provides physicians with an additional therapeutic option enabling them to continue the extended treatment with the regimen that best suits the benefit-risk-assessment of the individual patient.
2017-10-05	Janssen Research & Development, LLC	Results NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms jnj.com ↗ NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
2017-10-05	Bayer	Results Bayer’s NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms bayer.com ↗
2017-09-15	Bayer	Regulatory Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism bayer.com ↗ Bayer AG announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion to update the label for its oral Factor Xa inhibitor Xarelto® (rivaroxaban) to include a 10 mg once daily dose for the extended prevention of recurrent venous thromboembolism (VTE).
2017-08-27	Bayer	Results Bayer’s Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% bayer.com ↗ The benefit shown in the combined efficacy endpoint, major adverse cardiovascular events (MACE), for rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily was mainly driven by a significant reduction of stroke (42%) and CV death (22%).
2017-07-21	Bayer	Regulatory Xarelto in Combination with SAPT Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing PCI with Stent Placement bayer.com ↗
2017-05-01	Janssen Research & Development, LLC	Regulatory Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups jnj.com ↗ Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA
2017-03-18	Janssen Research & Development, LLC	Results New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism jnj.com ↗
2017-02-08	Janssen Research & Development, LLC	Results Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for Efficacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease jnj.com ↗ Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease
2016-11-14	Boehringer Ingelheim	Results First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care prnewswire.com ↗ Although treatment guidelines recommend OAC treatment for all NVAF patients at high stroke risk (i.e., CHADS 2 score ≥2), researchers found less than half (41.1 percent) of the study patients were treated with an OAC (warfarin, dabigatran, rivaroxaban or apixaban).
2015-12-07	Janssen Research & Development, LLC	Results Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis jnj.com ↗ Patients taking XARELTO® also had shorter length of hospital stays than those given standard anticoagulation.
2015-09-01	Janssen Research & Development, LLC	Results New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO® jnj.com ↗ The results found the rates and patterns of major bleeding in routine clinical practice were low (2.89 and 2.1 per 100 person-years, respectively) and generally consistent with those observed in Phase 3 clinical research.
2015-05-15	Janssen Research & Development, LLC	Results Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients jnj.com ↗ The data show the rates of major bleeding and fatal outcomes in elderly patients treated in routine clinical practice generally are consistent with those reported in Phase 3 clinical trials, which show a correlation between increased age and bleeding.
2015-05-14	Janssen Research & Development, LLC	Results New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015 jnj.com ↗
2015-03-30	Janssen Research & Development, LLC	Results New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO® Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits jnj.com ↗ A 27 percent reduction in hospital admissions when patients were treated with XARELTO® instead of LMWH and warfarin (p<0.001).
2015-03-16	Boehringer Ingelheim	Results New Data from Boehringer Ingelheim's GLORIA™-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated prnewswire.com ↗ Newer drugs known as novel oral anticoagulants (NOACs) accounted for 52.1 percent of anticoagulants prescribed (25.0 percent dabigatran, 20.5 percent rivaroxaban, and 6.6 percent apixaban).
2015-03-02	Janssen Research & Development, LLC	Results Findings to be Presented at Annual Scientific Session of the American College of Cardiology (ACC) About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO® jnj.com ↗
2015-01-14	Janssen Research & Development, LLC	Results Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO® jnj.com ↗ Of the 27,467 patients receiving XARELTO, an incidence of major bleeding was observed at 2.86 per 100 person-years, which was generally consistent with rates reported in the ROCKET-AF clinical trial.
2014-11-18	Janssen Research & Development, LLC	Results Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care jnj.com ↗ New data presented today at the American Heart Association (AHA) 2014 Scientific Sessions showed once-daily XARELTO® (rivaroxaban) is associated with significantly fewer hospitalization days and outpatient visits compared to warfarin in patients with non-valvular atrial fibrillation (NVAF).
2014-09-02	Janssen Research & Development, LLC	Results New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion jnj.com ↗ In addition, 0.61 percent of patients treated with XARELTO® were also observed to have a major bleeding event compared with 0.81 percent for VKA.
2014-01-16	Janssen Research & Development, LLC	Regulatory FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO® to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome jnj.com ↗ FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO® to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome
2013-09-20	Janssen Research & Development, LLC	Results Pooled Analysis Confirms XARELTO® has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE jnj.com ↗
2013-06-28	Janssen Research & Development, LLC	Regulatory FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome jnj.com ↗ FDA Issues Complete Response Letter for XARELTO ® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
2013-03-04	Janssen Research & Development, LLC	Regulatory FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome jnj.com ↗
2012-06-05	BioInvent International AB	Results BioInvent and ThromboGenics Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402 bioinvent.com ↗ The study showed that the incidence of venous thromboembolism (VTE) was similar with both drugs but patients receiving TB-402 had a significantly higher incidence of bleeding events.

All press releases naming this drug 116 releases

Date	Issuer	Release
Show all 116 releases opens the full record — a long page

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 397 sources stand behind the page.

Field	Value	Cited text
Known as	RIVAROXABAN	“AF patients with a CHA2DS2-VASc score >2 and no previous history of overt coronary disease, severe peripheral arterial disease (PAD) or major stroke will be registered and...” PMID 27558002 ↗ Aug 2016 392 “Patients will be chronically treated with NOAC including apixaban (2x5 mg or 2x2.5 mg depending on the dose reduction regimen) or dabigatran (2x150 mg or 2x110 mg depending on...” NCT06212674 ↗ “DOACs (eg Apixaban, dabigatran, edoxaban and rivaroxaban) are recommended by The National Institute for Health and Care Excellence (NICE) for those over 65 with AF and a...” NCT06322953 ↗ “NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice...” NCT01962545 ↗ “edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or...” NCT03968393 ↗ “Century Clot-guided rivaroxaban prophylactic therapy (2.5 mg twice daily, if the hypercoagulable state, defined as CR ≥24) in combination with standard DAPT could reduce LVT...” NCT06013020 ↗ “For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral...” NCT06021808 ↗ “For those randomized to group B (NOAC group), patients will be treated using a registered NOAC (rivaroxaban, apixaban or dabigatran, but preferentionally apixaban) at the dose...” NCT02426944 ↗ “The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month...” NCT03804697 ↗ “Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then...” NCT02331095 ↗ “Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.” NCT07497893 ↗ Show 382 more sources
Known as	BAY59-7939	“Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism” NCT00403767 ↗ 42 “One promising therapeutic option is rivaroxaban (BAY 59-7939, Rivaroxaban), an orally administered direct factor Xa inhibitor” NCT02438098 ↗ “Two Strategies of Rivaroxaban [JNJ39039039; BAY-59-7939] and One of Oral Vitamin K Antagonist” NCT01830543 ↗ “Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.” NCT00362232 ↗ “Drug: Xarelto (Rivaroxaban, BAY59-7939)” NCT00973245 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT02504216 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01853800 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01507051 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01442792 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00439777 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02309411 ↗ Show 32 more sources
Known as	JNJ39039039	“Two Strategies of Rivaroxaban [JNJ39039039; BAY-59-7939] and One of Oral Vitamin K Antagonist” NCT01830543 ↗
Known as	Rivaroxaban (Xarelto)	“Rivaroxaban (Xarelto)” NCT07011095 ↗ 2 “Rivaroxaban (Xarelto)” NCT03465735 ↗ “Rivaroxaban (Xarelto)” NCT01706146 ↗
Known as	Rivaroxaban accord	ChEMBL registry synonym — accepted as the source's own label CHEMBL198362 ↗
Known as	Rivaroxaban viatris (previously rivaroxaban mylan)	ChEMBL registry synonym — accepted as the source's own label CHEMBL198362 ↗
Known as	Rivaroxabana	“Xarelto 15 mg Rivaroxabana 15 mg” NCT05515120 ↗
Known as	Rovaltro	“Rivaroxaban (Rovaltro®) is a novel oral anticoagulant” NCT04569279 ↗
Known as	Xarelto	“Thromboprophylactic regimens Aspirin®(acetylsalicylic acid, AA, Bayer) 300mg/day or Xarelto® (rivaroxaban, factor Xa-inhibitor, Bayer) 10mg/day will be randomly(according to...” NCT02271399 ↗ 48 “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗ “A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19” NCT04504032 ↗ “Blood concentrations of rivaroxaban (Xarelto, Titusville, New Jersey) at 4 weeks were undetectable in 21% patients from Eastern Europe” PMID 33549557 ↗ Feb 2021 “Single administration of oral rivaroxaban in the form of Xarelto® 10mg tablets (Bayer Schering Pharma, Berlin, Germany).” NCT02970773 ↗ “Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)” NCT03148457 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto).” NCT06953726 ↗ “Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.” NCT00362232 ↗ “a new blood thinner called rivaroxaban (Xarelto) can be used to treat HIT” NCT01598168 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01442792 ↗ Show 38 more sources
Known as	Xarelto is the brand name for rivaroxaban	“Xarelto is the brand name for rivaroxaban” NCT01478282 ↗
Action	Inhibit	“an oral direct inhibitor of factor Xa” PMID 18579811 ↗ Jun 2008
Modality	Other / unclassified	“direct oral anticoagulant” NCT04794569 ↗
Route	Oral	“10 mg of oral rivaroxaban once daily” PMID 18579811 ↗ Jun 2008
Target	F10	“the direct factor Xa inhibitor rivaroxaban” NCT01812200 ↗